BIOLQ Quote, Financials, Valuation and Earnings

Milestone Scientific has a net margin of -13.16% compared to Biolase's net margin of -58.13%. Biolase's return on equity of -21668.17% beat Milestone Scientific's return on equity of -61.33%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22122.22%. On the other hand Milestone Scientific has an analysts' consensus of -- which suggests that it could grow by 131%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.929%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are larger than Milestone Scientific quarterly revenues of $2.5M. Biolase's net income of -$1.4M is higher than Milestone Scientific's net income of -$1.5M. Notably, Biolase's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 8.13x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of -13.16% compared to Biolase's net margin of 0.18%. Biolase's return on equity of -21668.17% beat Envista Holdings's return on equity of -32.33%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22122.22%. On the other hand Envista Holdings has an analysts' consensus of $21.33 which suggests that it could grow by 31.28%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.

Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Envista Holdings has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.59%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Envista Holdings quarterly revenues of $652.9M. Biolase's net income of -$1.4M is lower than Envista Holdings's net income of $1.2M. Notably, Biolase's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 1.12x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Sonendo has a net margin of -13.16% compared to Biolase's net margin of --. Biolase's return on equity of -21668.17% beat Sonendo's return on equity of --.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22122.22%. On the other hand Sonendo has an analysts' consensus of -- which suggests that it could fall by --. Given that Biolase has higher upside potential than Sonendo, analysts believe Biolase is more attractive than Sonendo.

Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Sonendo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sonendo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Sonendo pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are larger than Sonendo quarterly revenues of --. Biolase's net income of -$1.4M is higher than Sonendo's net income of --. Notably, Biolase's price-to-earnings ratio is -- while Sonendo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus -- for Sonendo. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of -13.16% compared to Biolase's net margin of -47.51%. Biolase's return on equity of -21668.17% beat Dentsply Sirona's return on equity of -32.39%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22122.22%. On the other hand Dentsply Sirona has an analysts' consensus of $20.20 which suggests that it could grow by 31.77%. Given that Biolase has higher upside potential than Dentsply Sirona, analysts believe Biolase is more attractive than Dentsply Sirona.

Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.383%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 4.18% to investors and pays a quarterly dividend of $0.16 per share. Biolase pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Dentsply Sirona quarterly revenues of $905M. Biolase's net income of -$1.4M is higher than Dentsply Sirona's net income of -$430M. Notably, Biolase's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 0.82x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.